Citations

Clear

3042 citation(s) found for "Kumar, S".

Advances of Cardiovascular MRI in Hypertrophic Cardiomyopathy
Blackshear, Joseph L., Mergo, Patricia J. , Parikh, Pragnesh , Batton, Kyle A., Shapiro, Brian P. , Kumar, Preetham, Kumar, Preetham , Ibrahim, El‐Sayed H.

Mayo Clinic

Future Cardiology | September 11, 2013 | Volume: 9 | Issue: 5 | Pages: 697-709

10.2217/fca.13.58 | PMID 24020671 Get It

Stroke Genetics Network (SiGN) Study
Arnett, Donna K. , Ay, Hakan , Brown, Robert D. , Benavente, Oscar, Bakker, Paul I. W. de , Dichgans, Martin , Doheny, Kimberly F. , Fornage, Myriam , Grewal, Raji P., Gwinn, Katrina , Conde, Jordi Jiménez, Johnson, Julie A. , Laurie, Cathy C. , Lee, Jin‐Moo , Lindgren, Arne, Markus, Hugh S. , McArdle, Patrick F. , McClure, Leslie A. , Mitchell, Braxton D. , Schmidt, Reinhold , Rexrode, Kathryn M. , Rich, Stephen S. , Rothwell, Peter M. , Sacco, Ralph L., Shuldiner, Alan R. , Słowik, Agnieszka , Sudlow, Cathie , Thijs, Vincent , Woo, Daniel , Worrall, Bradford B. , Wu, Ona , Kittner, Steven J. , collaborators, The SiGN study also includes the following, Anderson, Christopher D. , Andrén, Kerstin , Barrett, Kevin M. , Benner, Thomas, Bentley, Paul , Bevan, Steven, Biffi, Alessandro , Chapman, Sherita , Cheng, Yu‐Ching, Delavaran, Hossein , Gamble, Dale M., Giralt, Eva, Grazer, Anja, Gschwendtner, Andreas, Hegge, Caityln, Heitsch, Laura , Helenius, Johanna, Huq, Mohammed Saiful, Irie, Robert E., Jackson, Rebecca D. , Katschnig, Petra , Katsnelson, Michael , Khoury, Naïm , Kilinc, Selma, Kumar, Gyanendra, Langefeld, Carl D. , Lemmens, Robin , Malik, Shaneela , Melander, Olle , Nordström, Sara , Ois, Ángel , Ossi, Raid G., Peddareddygari, Leema Reddy , Pedersén, Annie , Pucek, Mateusz, Redfors, Petra , Rhodes, J. , Saraf, Neha, Schuerks, Markus, Seiler, Stephan , Sheikh, Huma U., Sparks, Mary J., Stoegerer, Eva, Temple, Ella, Valenti, Raffaella , Weir, David R. , Weissman, Darren, Woodfield, Rebecca, Yiin, Gabriel , Soliman, Elsayed Z. , Cushman, Mary , Kumar, Gyanendra , Bevan, Steve , Meschia, James F. , Cole, John W. , Jern, Christina , Jood, Katarina , Lindgren, Arne, Rosand, Jonathan M. , Rundek, Tatjana , Sharma, Pankaj Kumar , Wassertheil-Smoller, Sylvia W , collaborators, The SiGN study also includes the following, Andsberg, Gunnar , Arsava, Ethem Murat , Bevan, Steven, Brenner, David A. , Deline, Chris A. , Dziedzic, Tomasz , Holmegaard, Lukas , Kilinc, Selma, Kumar, Gyanendra, Labovitz, Daniel , Lanfranconi, Silvia , Li, Linxin , Norrving, Bo , Pera, Joanna , Rannikmäe, Kristiina , Ribasés, Marta , Southerland, Andrew M. , Sunyer, Jordi , Dichgans, Martin , Rich, Stephen S , Lemmens, Robin , Mitchell, Braxton D , Shuldiner, Alan R , Arnett, Donna K , Wu, Ona , Lee, Jin-Moo

Mayo Clinic

Stroke | September 11, 2013 | Volume: 44 | Issue: 10 | Pages: 2694-2702

10.1161/strokeaha.113.001857 | PMID 24021684 Get It

Background and Purpose— Meta-analyses of extant genome-wide data illustrate the need to focus on subtypes of ischemic stroke for gene discovery. The National Institute of Neurological Disorders and Stroke SiGN (Stroke Genetics Network) contributes substantially to meta-analyses that focus on specific subtypes of stroke. Methods— The National Institute of Neurological Disorders and Stroke SiGN includes ischemic stroke cases from 24 genetic research centers: 13 from the United States and 11 from Europe. Investigators harmonize ischemic stroke phenotyping using the Web-based causative classification of stroke system, with data entered by trained and certified adjudicators at participating genetic research centers. Through the Center for Inherited Diseases Research, the Network plans to genotype 10 296 carefully phenotyped stroke cases using genome-wide single nucleotide polymorphism arrays and adds to these another 4253 previously genotyped cases, for a total of 14 549 cases. To maximize power for subtype analyses, the study allocates genotyping resources almost exclusively to cases. Publicly available studies provide most of the control genotypes. Center for Inherited Diseases Research–generated genotypes and corresponding phenotypes will be shared with the scientific community through the US National Center for Biotechnology Information database of Genotypes and Phenotypes, and brain MRI studies will be centrally archived. Conclusions— The Stroke Genetics Network, with its emphasis on careful and standardized phenotyping of ischemic stroke and stroke subtypes, provides an unprecedented opportunity to uncover genetic determinants of ischemic stroke.
Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels
Greenberg, Alexandra J. , Walters, Denise K., Kumar, Shaji , Rajkumar, S. Vincent , Jelinek, Diane F., Rajkumar, S Vincent

Mayo Clinic

European Journal of Haematology | September 2, 2013 | Volume: 91 | Issue: 6 | Pages: 504-513

10.1111/ejh.12192 | PMID 23992230 Get It

AbstractThe introduction of novel immunomodulatory drugs (IMiDs) has dramatically improved the survival of patients with multiple myeloma (MM). While it has been shown that patients with specific cytogenetic subtypes, namely t(4;14), have the best outcomes when treated with bortezomib‐based regimens, the relationship between cytogenetic subtypes and response to IMiDs remains unclear. Using DNA synthesis assays, we investigated the relationship between cytogenetic subtype and lenalidomide response in a representative panel of human myeloma cell lines (HMCLs). We examined HMCL protein expression levels of the lenalidomide target cereblon (CRBN) and its downstream target interferon regulatory factor‐4 (IRF4), which have previously been shown to be predictive of lenalidomide response in HMCLs. Our results reveal that lenalidomide response did not correlate with specific cytogenetic translocations. There were distinct groups of lenalidomide‐responsive and non‐responsive HMCLs, as defined by inhibition of cellular proliferation; notably, all of the hyperdiploid HMCLs fell into the latter category. Repeated dosing of lenalidomide significantly lowered the IC50 of the responsive HMCL ALMC‐1 (IC50 = 2.6 μm vs. 0.005 μm, P < 0.0001), but did not have an effect on the IC50 of the non‐responsive DP‐6 HMCL (P > 0.05). Moreover, no association was found between lenalidomide responsiveness and CRBN and IRF4 expression. Our data indicate that lenalidomide sensitivity is independent of cytogenetic subtype in HMCLs. While CRBN and IRF4 have been shown to be associated with response to lenalidomide in patients, these findings do not translate back to HMCLs, which could be attributable to factors present in the bone marrow microenvironment.
Routine cholecystectomy during Roux-en-Y gastric bypass with or without choledocholithiasis
Baron, Todd H. , Garg, Sushil Kumar

Mayo Clinic

Cochrane Database of Systematic Reviews | August 26, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/14651858.cd010715 Get It

A multicenter evaluation of pandemic influenza A/H1N1 in hematopoietic stem cell transplant recipients
Reid, Gail , Huprikar, Shirish , Patel, Gopi , Mossad, Sherif B. , Levi, Marilyn E. , Gregg, Kevin , Humar, Atul , Adams, William , Kumar, Deepali , Razonable, Raymund R. , Shoham, Shmuel

Mayo Clinic

Transplant Infectious Disease | July 25, 2013 | Volume: 15 | Issue: 5 | Pages: 487-492

10.1111/tid.12116 | PMID 23890293 Get It

AbstractBackgroundHematopoietic stem cell transplant (HSCT) recipients have increased morbidity from respiratory viral infections. Pandemic influenza A – A(H1N1)/pdm09 – in 2009–2010 was associated with increased severity of illness in patients with underlying co‐morbidities including HSCT, but the factors that contribute to severe disease in HSCT patients are not well characterized.MethodsWe conducted a multicenter review of microbiologically proven influenza A(H1N1)pdm09 in the HSCT population between April 2009 and April 2010 to determine factors that are associated with severe disease.ResultsWe identified 37 adult patients (26 allogeneic and 11 autologous HSCT recipients). Median time from transplant to diagnosis was 411 days (range 4 days–14.9 years). Three cases were hospital acquired. Twenty‐eight of 37 (75.7%) had confirmed A(H1N1)pdm09. Presumed viral lower respiratory tract infection was present in 12/37 (32.4%) patients. Antiviral therapy was given to 33/37 (89%) patients, primarily oseltamivir (n = 24) and oseltamivir before or after another antiviral (n = 8). Excluding those with nosocomial A(H1N1)pdm09, 18/34 (52.9%) were hospitalized and 6 (33%) required admission to an intensive care unit. Mortality within 30 and 60 days of symptom onset was 7/37 (18.9%) and 11/37 (29.7%), respectively. Factors associated with mortality included nosocomial acquisition (P = 0.023), receipt of mycophenolate mofetil (P = 0.001), or antilymphocyte antibody (P = 0.005) within the past 6 months, reduced‐intensity conditioning (P = 0.027), and bacteremia (P = 0.021).ConclusionsA(H1N1)pdm09 infection was particularly severe in HSCT recipients, specifically among those receiving augmented immunosuppression for graft‐versus‐host disease. The high mortality of the nosocomial cases highlights the need for strict infection‐control measures in hospitals during influenza outbreaks.
Serum 25-hydroxyvitamin D concentrations and waning pneumococcal antibody titers among individuals with atopy
Kumar, Rajiv , Kita, Hirohito , Juhn, Young J. , Ryoo, Eell, Ryoo, Eell , Kita, H , Kumar, Rajiv

Mayo Clinic

Allergy and Asthma Proceedings | July 24, 2013 | Volume: 34 | Issue: 4 | Pages: 370-377

10.2500/aap.2013.34.3656 | PMID 23883602 Get It

Implications of continued response after autologous stem cell transplantation for multiple myeloma
Dispenzieri, Angela , Lacy, Martha Q. , Lin, Yi , Hayman, Suzanne R. , Dingli, David , Kapoor, Prashant , McCurdy, Arleigh , Kumar, Shaji , Gonsalves, Wilson I. , Gertz, Morie A. , Singh, Preet Paul , Gupta, Vinay Kumar , Buadi, Francis K. , Dispenzieri, Angela , Dingli, David , Lin, Yi , McCurdy, Arleigh

Mayo Clinic

Blood | July 18, 2013 | Volume: 122 | Issue: 10 | Pages: 1746-1749

10.1182/blood-2013-03-492678 | PMID 23863899 Get It

Key Points A continued monoclonal protein response after ASCT in the absence of further therapy is prognostic in MM patients.
Temporal Trends in the Diagnosis and Management of Childhood Obesity/Overweight in Primary Care
Nader, Nicole, Singhal, Vibha , Javed, Asma , Weaver, Amy L. , Kumar, Seema , Nader, Nicole

Mayo Clinic

Journal of Primary Care & Community Health | July 15, 2013 | Volume: 5 | Issue: 1 | Pages: 44-49

10.1177/2150131913495739 | PMID 24327587 Get It

Objective: To determine the temporal trends in diagnosis and management of pediatric overweight/obesity by primary care providers at a single medical center. Patients: Children 2 to 18 years old undergoing a general medical examination during 3 calendar years (2003, 2006, and 2009). The number of visits for general medical examination were 6390 in 2003, 6646 in 2006, and 7408 in 2009. Methods: We performed a retrospective review of the electronic medical records for weight related diagnostic and/or management terms and laboratory screening in children with body mass index at or greater than the 85th percentile (n = 1630 in 2003, 1495 in 2006, and 1730 in 2009). Results: There was a significant increase in the diagnosis of obesity among obese children seen in 2009 (53.3%) compared with 2006 (36%, P < .001) and 2003 (24.3%, P < .001). Weight-related counseling was documented in a higher proportion of obese children in 2009 (49.4%) compared with 2006 (34.8%) and 2003 (26.6%). There was a significant increase in counseling regarding screen time in 2009 compared with 2006. A significant increase in screening for nonalcoholic fatty liver disease was also noted (30.5% in 2009 vs 21.9% in 2006, P = .018). Conclusions: There has been steady improvement in the rates of obesity diagnosis and obesity-related counseling by primary care providers. However, continued efforts to increase awareness of these issues are needed as nearly half of obese children remained undiagnosed and recommended laboratory screening for obesity-related comorbidities was performed in only a third of obese children.
Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
Anderson, S. Keith , Lafky, Jackie M., Uhm, Joon H. , Kumar, Shaji , Kimlinger, Teresa K. , Northfelt, Donald W. , Flynn, Patrick J. , Jaeckle, Kurt A. , Buckner, Jan C. , Galanis, Evanthia , Giannini, Caterina , Kaufmann, Timothy J.

Mayo Clinic

Clinical Cancer Research | July 6, 2013 | Volume: 19 | Issue: 17 | Pages: 4816-4823

10.1158/1078-0432.ccr-13-0708 | PMID 23833308 Get It

Abstract Purpose: We hypothesized that vertical blockade of VEGF signaling by combining bevacizumab with sorafenib in patients with recurrent glioblastoma would result in a synergistic therapeutic effect. We also investigated whether VEGF, VEGFR2 and hypoxia-inducible factor-1α single-nucleotide polymorphisms (SNP), circulating biomarkers of angiogenesis, and MRI markers such as apparent diffusion coefficient (ADC) are correlated with treatment efficacy and/or toxicity. Experimental Design: Patients received bevacizumab (5 mg/kg every 2 weeks) with sorafenib (200 mg twice a day, weekly, days 1–5; group A). Due to toxicity, the starting sorafenib dose was subsequently modified to 200 mg every day (group B). Results: Fifty-four patients were enrolled: 19 patients in group A and 35 in group B. Objective response rate was 18.5% with median duration of 6.7 months (range 0.5–24.1 months). Six-month progression-free survival (PFS6) was 20.4% (11/54), and median overall survival (OS) was 5.6 months [95% confidence interval (CI), 4.7–8.2]; outcome was similar between the two dose groups. We identified SNPs in the VEGF and VEGFR2 promoter regions, which were associated with PFS6 (P &lt; 0.022). Among molecular markers of angiogenesis, a higher log2 baseline level of stromal cell–derived factor-1 was associated with PFS6 success (P = 0.04). Circulating endothelial cells decreased during treatment with subsequent increase at disease progression (P = 0.022). Imaging analysis showed a trend associating ADC-L with poor outcome. Conclusions: The bevacizumab/sorafenib combination did not improve outcome of patients with recurrent glioblastoma versus historic bevacizumab-treated controls. Biologic markers of response and resistance to bevacizumab in gliomas were identified which merit prospective validation. Clin Cancer Res; 19(17); 4816–23. ©2013 AACR.
Radiation Exposure in the Cardiac Catheterization Lab
Levy, Michael S. , Kumar, Preetham

Mayo Clinic

Catheterization and Cardiovascular Interventions | June 21, 2013 | Volume: 82 | Issue: 1 | Pages: 17-18

10.1002/ccd.25027 | PMID 23788383 Get It